FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      
           
This page is updated frequently with new Rheumatoid Arthritis-related patent applications. Subscribe to the Rheumatoid Arthritis RSS feed to automatically get the update: related Rheumatoid RSS feeds. RSS updates for this page: Rheumatoid Arthritis RSS RSS


Date/App# patent app List of recent Rheumatoid Arthritis-related patents
03/26/15
20150087674
 Compositions and methods for the treatment of severe pain patent thumbnailnew patent Compositions and methods for the treatment of severe pain
The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
03/26/15
20150087660
 Compositions and methods for the treatment of chronic diseases and inflammatory disorders patent thumbnailnew patent Compositions and methods for the treatment of chronic diseases and inflammatory disorders
The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of chronic diseases and inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
03/26/15
20150087646
 Triazolone compounds as mpges-1 inhibitors patent thumbnailnew patent Triazolone compounds as mpges-1 inhibitors
The present disclosure is directed to compounds of formula (i), and pharmaceutically acceptable salts thereof, as mpges-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin e synthase-1 (mpges-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases..
Glenmark Pharmaceuticals S.a.
03/26/15
20150087626
 Cyclic amine derivatives as ep4 receptor antagonists patent thumbnailnew patent Cyclic amine derivatives as ep4 receptor antagonists
The present invention therefore relates to novel compounds which are selective antagonists of the ep4 subtype of pge2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of prostaglandin e mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.. .
03/26/15
20150087548
 Marker sequences for rheumatoid arthritis and use thereof patent thumbnailnew patent Marker sequences for rheumatoid arthritis and use thereof
The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof..
Protagen Aktiengesellschaft
03/26/15
20150086556
 Anti-activin a antibodies and uses thereof patent thumbnailnew patent Anti-activin a antibodies and uses thereof
The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.
03/19/15
20150080356
 Method for improving therapy for autoimmune diseases such as rheumatoid arthritis patent thumbnailMethod for improving therapy for autoimmune diseases such as rheumatoid arthritis
In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases.
Toyama Chemical Co., Ltd.
03/19/15
20150080245
 Rheumatoid arthritis diagnosis kit patent thumbnailRheumatoid arthritis diagnosis kit
The present invention aims to diagnose rheumatoid arthritis more accurately and rapidly, and relates to a method and a kit for diagnosing rheumatoid arthritis, based on the detection of citrullinated autoantigens in a test sample.. .
Catholic University Industry-academic Cooperation Foundation
03/12/15
20150073030
 Tcr/mhcii-collagen interaction inhibitors useful for the treatment of rheumatoid arthritis patent thumbnailTcr/mhcii-collagen interaction inhibitors useful for the treatment of rheumatoid arthritis
The t cells specific to human collagen type ii, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of hla-dr4. The protein-protein interactions between the t cell receptor (tcr) and the type ii collagen linked to the allele mhc of class ii hla-dr4 may thus represent the target for the development of new drugs against rheumatoid arthritis.
UniversitÀ Cattolica Del Sacro Cuore
03/12/15
20150072980
 Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis patent thumbnailSubstituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc
03/05/15
20150064196

Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof


These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of bruton's tyrosine kinase (btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, b-cell malignancies, systemic lupus, erythematosus or other disorders.. .
03/05/15
20150064195

Uses and compositions for treatment of rheumatoid arthritis


The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof.
03/05/15
20150064194

Uses and compositions for treatment of rheumatoid arthritis


The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof.
03/05/15
20150064177

Therapeutic uses of humanized antibodies against alpha-4 integrin


The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, aids dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury..
Biogen Idec Ma Inc.
03/05/15
20150064168

Cadherin-11 inhibitors and methods of use thereof


Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis..
Georgetown University
03/05/15
20150064132

Treatment methods for rheumatoid arthritis


The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein.
02/26/15
20150057283

Reverse-turn mimetics and method relating thereto


Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents.
Choongwae Pharma Corporation
02/26/15
20150056212

Uses and compositions for treatment of rheumatoid arthritis


The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof.
02/26/15
20150056208

Novel antibodies


Autoimmune reactions to certain epitopes of self antigens most likely contribute to the development of rheumatoid arthritis. Often these epitopes are citrullinated.
Vilara Ab
02/26/15
20150056205

Steroid sparing agents and methods of using same


This invention relates generally to methods of treating inflammatory bowel diseases (ibd), asthma, crohn's disease (cd), multiple sclerosis (ms), rheumatoid arthritis (ra), graft versus host disease (gvhd), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions..
Biogen Idec Ma Inc.
02/19/15
20150051196

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
02/19/15
20150050291

Detection and modulation of rheumatoid arthritis


A method for detecting and/or monitoring a chronic inflammation condition associated with rheumatoid arthritis. The method comprises the steps of: (i) collecting a sample; (ii) detecting in the sample, one or more of a hmgn1 protein, a lcp-1 protein, a prtn3 protein, a sec22b protein, and a pygl glycogen phosphorylase protein thereby producing a result; and (iii) correlating the result with a control.
Universityof Manitoba
02/19/15
20150050286

Anti-ngf antibodies and methods using same


The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain..
Rinat Neuroscience Corp.
02/12/15
20150045361

Heterocyclic compounds and their uses


Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.
02/12/15
20150045244

Method for determining rheumatoid arthritis activity indicator, and biomarker used therein


The object of the invention is to find a simple biomarker with high reproducibility with regard to a method for evaluating the activity of the condition and progression of rheumatoid arthritis disease and provide an effective evaluation method therefor. The invention is to provide a method for determining the value of a rheumatoid arthritis-linked indicator in a subject, the method being characterized by comprising a step for measuring the amount of expression of the fam20a gene in blood collected from the subject, a step for analyzing the measured amount of expression using a gene expression profile that is prepared in advance and correlates with the indicator and a step for estimating the value of the indicator in the subject on the basis of the analysis results..
Keio University
02/05/15
20150038527

Furopyridine derivatives


In which r1, r2 and r4 have the meanings indicated in claim 1, are inhibitors of syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and/or systemic lupus. .
02/05/15
20150037349

Anti-tumor necrosis factor-alpha agents and uses thereof


The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against tumor necrosis factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-tumor necrosis factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis.
Technophage, InvestigaÇÃo E Desenvolvimento Em Biotecnologia, Sa
01/29/15
20150031695

Small molecule compounds for targeting inflammatory conditions


Small molecule compounds for the treatment of inflammatory conditions, and pharmaceutical compositions and methods relating thereto. The compositions may be used for the treatment of conditions such as multiple sclerosis, type 2 diabetes, psoriasis, rheumatoid arthritis, hashimoto's thyroiditis, and crohn's disease.
01/29/15
20150030665

Composition and treating connective tissue damage


The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, n-acetyl d-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (djd), post surgical djd, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, small intestine tissue damage, blood cell damage, and plasma damage.
Arthrodynamic Technologies, Animal Health Division, Inc.
01/22/15
20150025066

Cyclic diaminopyrimidine derivatives


In which a, l1, l2, x and y have the meanings indicated in claim 1, are inhibitors of syk, and can be employed, inter alia, for the treatment of rheumatoid arthritis.. .
01/22/15
20150025058

8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors


Are inhibitors of syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and/or systemic lupus. .
01/22/15
20150025056

Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases


Its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring a substituent groups are fully defined in the following disclosure. The compounds of formula i are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of mmps is desirable..
01/22/15
20150025050

Corticosteroids for the treatment of joint pain


Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
Flexion Therapeutics, Inc.
01/22/15
20150024075

Phytocomposition for the treatment of pain related to joint diseases


It is disclosed a phytocomposition which includes: (a) 0.01 wt % to 26 wt % of arnica montana extract; (b) 0.01 wt % to 26 wt % of rosmarinus officinalis extract; (c) 0.01 wt % to 26 wt % of zingiber officinale extract; and (d) 0.01 wt % to 26 wt % of boswellia serrate extract. Said phytocomposition can be used in combination with a pharmaceutically acceptable carrier in order to obtain a pharmaceutical composition that can be used for treating muscle, arthritic and rheumatic pain in a patient, caused by joint diseases, in particular rheumatoid arthritis, osteoarthritis, fibromyalgia, gouty arthritis, psoriatic arthritis, lupus and juvenile arthritis..
01/15/15
20150018347

Spirocyclic compounds as modulators of chemokine receptor activity


Or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
01/15/15
20150017266

Compositions and methods for relieving symptoms of rheumatoid arthritis and related illnesses


Compositions and methods for relieving symptoms of rheumatoid arthritis (ra) and related illnesses are disclosed. It appears that the primary cause of ra is a sensitivity or hypersensitivity to potassium and/or vitamin c, or too much potassium and/or vitamin c in the diet.
01/08/15
20150011767

Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints


The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University
01/08/15
20150010627

New pharmaceutical compositions of flurbiprofen and glucosamin


The present invention relates to new pharmaceutical compositions of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to new pharmaceutical compositions for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis..
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
01/08/15
20150010573

Il-17 antibody formulation


The present invention provides stabilized pharmaceutical formulations for anti-il-17 antibodies, comprising e.g. Citrate, sodium chloride and polysorbate-80 at ph 5.7.
Eli Lilly And Company
12/25/14
20140378537

Treatment of th17 mediated inflammatory diseases


The present invention provides methods and means to reduce inflammation associated with irf-4, ap-1 and th17 mediated diseases. In particular, the invention provides methods and means to treat multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis and related conditions..
Genentech, Inc.
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140378453

2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors


The present invention relates to novel inhibitors of factors viia, ixa, xa, xia, in particular factor viia, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed..
Pharmacyclics, Inc.
12/25/14
20140378384

Polypeptides in preparation of drugs for treatment or prevention of rheumatoid arthritis


A series of polypeptides presenting high integrin affinity and bonding capacity is provided. Three polypeptides among said series can be adopted in prevention and treatment of rheumatoid arthritis.
12/25/14
20140377387

Compositions and methods for modulating lipid composition


This disclosure relates to novel herbal compositions comprising extracts of rosemary and oregano, and methods of using the herbal compositions to modulate inflammatory potential. One or both of the extracts may be supercritical extracts.
Board Of Regents Of The University Of Texas System
12/25/14
20140377282

Anti-kdr antibodies and methods of use


The present invention provides anti-kdr monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant vegf or kdr expression and/or activity.. .
Apexigen, Inc.
12/18/14
20140371250

Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors


The present invention relates to chemical compounds of formula (i) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by tnf-α or by pde4, including but not limited to rheumatoid arthritis.. .
High Point Pharmaceuticals, Llc
12/18/14
20140371242

Azathioprine oral suspensions and methods of use


Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
12/11/14
20140364401

Antispasmodic 1,2-diols and 1,2,3-triols


The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
12/11/14
20140363497

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
12/04/14
20140356437

Corticosteroids for the treatment of joint pain


Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
12/04/14
20140356391

Amino acid sequences for clinical remission of psoriasis and related diseases.


Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of cutaneous leishmaniasis, psoriasis, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, seborrheic dermatitis and skin papilloma. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells.
11/27/14
20140349998

Pyrrolopyrimidines as janus kinase inhiitors


The instant invention provides compounds of formula i which are jak3 inhibitors. Specifically, the compounds of formula i are pyrrolo[2,3-d]pyrimidine derivative compounds.
11/27/14
20140349989

Compounds and therapeutic uses thereof


The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, t-cell mediated autoimmune disease, ischemia, and complications associated with these diseases and disorders.. .
11/27/14
20140349980

Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage


The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.. .
11/27/14
20140348784

Compositions and methods for treatment of angiogenesis in pathological lesions


Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions.
11/20/14
20140342378

Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis


The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue.
11/20/14
20140341887

Methods for treating, diagnosing, and monitoring rheumatoid arthritis


Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents..
11/13/14
20140336162

Locally administrated low doses of corticosteroids


This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot..
11/13/14
20140336121

Factor h for treatment of rheumatoid arthritis


The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising factor h (fh). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the factor h..
11/13/14
20140336069

Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit


Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.. .
11/13/14
20140335081

Treatment for rheumatoid arthritis


Treatment of rheumatoid arthritis (ra) to provide clinical benefit in patients, including decrease in das28-crp by more than 1.2 and/or improvement determined by acr20, acr50 or acr70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to tyr-leu-asp-phe-gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (gm-csfrα). Use of gm-csfrα inhibitors such as mavrilimumab to enhance clinical benefit in ra patients receiving stable dose of dmards, particularly methotrexate..
11/06/14
20140329815

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
11/06/14
20140329799

Aminopyrimidinones as interleukin receptor-associated kinase inhibitors


This invention relates to aminopyrimidinone compounds of formula (i) that are inhibitors of interleukin receptor-associated kinases, in particular irak-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.. .
10/30/14
20140322757

Antibodies that bind colony stimulating factor 1 receptor (csf1r)


Antibodies that bind csf1r are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind csf1r are also provided.
10/30/14
20140322274

Therapeutic agents


A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside gm-1 associated activity in an amount effective to treat the disease.. .
10/30/14
20140322239

Anti-il-6 receptor antibodies and methods of use


The present invention provides anti-il-6r monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.. .
10/30/14
20140322211

Tenascin-c and use thereof in rheumatoid arthritis


The present invention provides a method of determining the rheumatoid arthritis status of a subject, or the progression of rheumatoid arthritis, or the appropriate treatment for a subject with rheumatoid arthritis, comprising the steps of (a) determining the level of tenascin-c in a sample from said subject; and (b) comparing the level of tenascin-c determined in step (a) with one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis.


Popular terms: [SEARCH]

Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













1.7447

3973

3 - 0 - 71